Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study.

J Diabetes Metab Disord · 2022 · PMC9167339 · PMID 35673518

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Other studies also reported similar UTI rates between treatment groups [ 31 , 37 , 52 , 53 ] while a pooled analysis (OR 1.15; 95% CI 1.00, 1.33; p = 0.047) [ 38 ] and a retrospective cohort study in Korea (HR 1.05; 95% CI 1.00, 1.11; p = 0.047) [ 54 ] reported increased risk of UTIs with SGLT2 inhibitors which was borderline significant.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.